AbCellera Biologics Inc. Common Shares (ABCL)
Stock · NASDAQ · Health Care
$11.35as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$3.46
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $1.92B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How AbCellera Biologics Inc. Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
AbCellera Biologics Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- ABCLAbCellera Biologics Inc. Common Shares$11.35▼ 8.47%Market cap $1.92BP/E —
- OCULOcular Therapeutix Inc. Common Stock$10.36▼ 4.25%Market cap $1.92BP/E —$6.23$16.44
- ANIPANI Pharmaceuticals Inc.$72.83▼ 0.93%Market cap $1.86BP/E 18.72$70.15$99.5
- NBTXNanobiotix S.A. American Depositary Shares$41.28▼ 8.59%Market cap $1.83BP/E —$7.02$47.66
- CMPSCOMPASS Pathways Plc American Depository Shares$13.71▼ 6.35%Market cap $1.83BP/E —$4.4$15.4
- ZBIOZenas BioPharma Inc. Common Stock$31.29▼ 4.08%Market cap $2.03BP/E —$13.5$44.6
- BCAXBicara Therapeutics Inc. Common Stock$23.42▼ 5.70%Market cap $1.81BP/E —$10.3$30.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABCL AbCellera Biologics Inc. Common Shares | $1.92B | — | $11.35 | ▼ 8.47% | |
| OCUL Ocular Therapeutix Inc. Common Stock | $1.92B | — | $10.36 | ▼ 4.25% | $6.23$16.44 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 18.72 | $72.83 | ▼ 0.93% | $70.15$99.5 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $41.28 | ▼ 8.59% | $7.02$47.66 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $13.71 | ▼ 6.35% | $4.4$15.4 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $31.29 | ▼ 4.08% | $13.5$44.6 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $23.42 | ▼ 5.70% | $10.3$30.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- What's Going on With AbCellera Biologics Stock On Wednesday?Benzinga · 8/12/2026
- National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · 8/12/2026
- AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is FadingSeekingAlpha · 8/11/2026
- AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common SharesBenzinga · 8/11/2026
- Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30Benzinga · 8/11/2026
- Here are the top movers in Monday's session.ChartMill · 8/10/2026
- AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes TranscriptSeekingAlpha · 8/10/2026
- There are notable gap-ups and gap-downs in today's session.ChartMill · 8/10/2026
Insider Activity
Insider Actions →Acquired
909.5K
Disposed
0
- Victor Sandor · July 1, 2026 · Grant152.2K
- Seely Lynn · July 1, 2026 · Grant152.2K
- John S. Montalbano · June 11, 2026 · Grant111.7K
- Quake Stephen · June 11, 2026 · Grant111.7K
- Michael R. Hayden · June 11, 2026 · Grant111.7K
- Andrew Booth · June 3, 2026 · Option Exercise250.0K @ $0.19
- John S. Montalbano · May 14, 2026 · Buy20.0K @ $4.77
Institutional Ownership
March 31, 2026
- Total shares held
- 129.17M
- Total value held
- $446.06M
- Institutional holders
- 135
Top holders this quarter
- Unknown30.28M
- Unknown13.36M
- Unknown10.56M
- Unknown9.56M
- Unknown7.58M
- Unknown5.48M
- Unknown4.21M
- Unknown4.11M
- Unknown4.04M
- Unknown4.02M
See the full, filterable feed with live charts on the MarketWall dashboard.